P523 Improvement of quality of life and continence in patients with distal ulcerative colitis treated by mesalazine: QUARTZ study
T. Paupard1, F. Gonzalez2, L. Siproudhis3, L. Peyrin-Biroulet4, Thierry Paupard
1Centre Hospitalier de Dunkerque, Gastroenterology, Dunkerque, France, 2Cabinet d’Hépato Gastroentérologie, Gastroenterology, Nîmes, France, 3CHU Pontchaillou, Gastroenterology, Rennes, France, 4CHU Brabois, Gastroenterology, Vandœuvre-lès-Nancy, France
Background
There is no robust data which analysed quality of life, functional disability and continence of patients with distal UC. QUARTZ is the first prospective study in this situation.
Methods
Observational, prospective and multicentric study involving public and private French gastroenterologist to recruit patients with mild to moderate (Mayo score ≥ 3 and ≤ 10) active proctitis or proctosigmoiditis (<20 cm) and under mesalazine for induction treatment. The patients followed for 12 months (±2 months). The primary objective was the quality of life evaluated by Short Inflammatory Bowel Disease (SIBDQ) at 8 weeks (±4 months). The functional disability and incontinence have been evaluated by IBD-Disability Index and Cleveland questionnaires.
Results
From December 2015 to November 2016, 117 patients were recruited. Data of 93 patients have been analysed and results are reported on Table 1. Among the 93 patients, 75 (81%) reached a clinical remission at week 8 with a SIBDQ score improvement of 6.7 ± 7.1 point (
| Mild, | Moderate, | Total | |
| Gender, M/F | 26/22 | 24/21 | 50/43 |
| Age, average ± SD (years) | 43,7 ± 13,6 | 41,5 ± 15,6 | 42,7 ± 14,5 |
| UC diagnosed < 1 year, | 21(44%) | 28(62%) | 49(53%) |
| Oral mesalazine | 16(17%) | ||
| Topical mesalazine | 44(47%) | ||
| Oral and local | 33(36%) | ||
| Combination with steroid | 7(15%) | 5(11%) | 12(13%) |
| SIBDQ baseline, average ± SD | 40,4 ± 7,1 | 35,9 ± 9,1 | 38,2 ± 8,4 |
| SIBDQ week 8 | 44,8 ± 6,1* | 43,3 ± 7,6* | 44,1 ± 6,8* |
| IBD-DI baseline, average ± SD | 21,5 ± 19,2 | 32,7 ± 20,3 | 26,9 ± 20,4 |
| IBD-DI week 8, average ± SD | 14,0 ± 15,3 | 17.6 ± 16,0 | 15,8 ± 15,7 |
| Cleveland ≥ 4 baseline, n (%) | 9(19%) | 11(24%) | 20(22%) |
| Cleveland ≥ 4 week 8, n (%) | 3(6,3%) | 6(13,3%) | 9(9,7%) |
*
Conclusion
For patients with distal ulcerative colitis treated by mesalazine, quality of life, functional disability and continence have been improved at 8 weeks of treatment despite a poor adherence.